These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 19774657)
1. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. Urva SR; Yang VC; Balthasar JP J Pharm Sci; 2010 Mar; 99(3):1582-600. PubMed ID: 19774657 [TBL] [Abstract][Full Text] [Related]
2. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer. Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609 [TBL] [Abstract][Full Text] [Related]
3. Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts. Urva SR; Balthasar JP MAbs; 2010; 2(1):67-72. PubMed ID: 20081377 [TBL] [Abstract][Full Text] [Related]
4. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029 [TBL] [Abstract][Full Text] [Related]
5. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795 [TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models. Polli JR; Engler FA; Balthasar JP J Pharm Sci; 2019 Jan; 108(1):674-691. PubMed ID: 30321546 [TBL] [Abstract][Full Text] [Related]
7. An ELISA for quantification of T84.66, a monoclonal anti-CEA antibody, in mouse plasma. Urva SR; Yang VC; Balthasar JP J Immunoassay Immunochem; 2010; 31(1):1-9. PubMed ID: 20391013 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. Abuqayyas L; Balthasar JP AAPS J; 2012 Sep; 14(3):445-55. PubMed ID: 22528507 [TBL] [Abstract][Full Text] [Related]
9. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Shah DK; Betts AM J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261 [TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Garg A; Balthasar JP J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of decreasing liver uptake of 111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice. Beatty BG; O'Conner-Tressel M; Do T; Paxton RJ; Beatty JD Cancer Res; 1990 Feb; 50(3 Suppl):846s-851s. PubMed ID: 2297732 [TBL] [Abstract][Full Text] [Related]
12. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ferl GZ; Wu AM; DiStefano JJ Ann Biomed Eng; 2005 Nov; 33(11):1640-52. PubMed ID: 16341929 [TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228 [TBL] [Abstract][Full Text] [Related]
14. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer. Abuqayyas L; Balthasar JP J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417 [TBL] [Abstract][Full Text] [Related]
15. Carcinoembryonic antigen and alpha-fetoprotein expression and monoclonal antibody targeting in a human hepatoma/nude mouse model. Wang ZF; Stein R; Sharkey RM; Goldenberg DM Cancer Res; 1990 Feb; 50(3 Suppl):869s-872s. PubMed ID: 1688735 [TBL] [Abstract][Full Text] [Related]
16. Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies. Iwano J; Shinmi D; Masuda K; Murakami T; Enokizono J Drug Metab Dispos; 2019 Nov; 47(11):1240-1246. PubMed ID: 31533926 [TBL] [Abstract][Full Text] [Related]
17. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody. Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476 [TBL] [Abstract][Full Text] [Related]
19. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Kenanova V; Olafsen T; Crow DM; Sundaresan G; Subbarayan M; Carter NH; Ikle DN; Yazaki PJ; Chatziioannou AF; Gambhir SS; Williams LE; Shively JE; Colcher D; Raubitschek AA; Wu AM Cancer Res; 2005 Jan; 65(2):622-31. PubMed ID: 15695407 [TBL] [Abstract][Full Text] [Related]
20. Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer. Thomas VA; Balthasar JP AAPS J; 2016 Jul; 18(4):923-32. PubMed ID: 27029796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]